Early adventures in drug metabolism: 4. Diphenylhydantoin (phenytoin).
This series comes to a close with a discussion of problems related to phenytoin metabolites, their discovery and role in the toxicity of this drug. More particularly, it looks at the influence of the p-hydroxyphenyl metabolite of phenytoin (HPPH) on the metabolic disposition of the parent compound, and the relationship of the dihydrodiol metabolite to the putative presence of arene oxides. The question of pro-drugs is examined, including factors that may influence any decision to market the drug. The role of organizational committees and the good that can be accomplished outside the confines of the laboratory are also discussed.
A J
AJ
Glazko
D000818:Animals; D004305:Dose-Response Relationship, Drug; D005965:Glucuronates / Q000378:metabolism; D006801:Humans; D006900:Hydroxylation; D008253:Macaca mulatta; D010672:Phenytoin / Q000031:analogs & derivatives / Q000378:metabolism* / Q000493:pharmacokinetics; D011355:Prodrugs / Q000378:metabolism
D005965:Glucuronates; D011355:Prodrugs; C027364:5-(3-hydroxyphenyl)-5-phenylhydantoin; D010672:Phenytoin